Boston Scientific Corporation ($BSX) Stock Forecast: Up 5.5% Today

What is Boston Scientific Corporation?

Boston Scientific Corporation (NYSE: BSX) Market: Boston Scientific Corporation (BSX) had a strong bullish movement today amidst positive news and financial performance in the first quarter of 2025.

Why is Boston Scientific Corporation going up?

BSX stock is up 5.5% on Apr 23, 2025 17:23

• Boston Scientific Corporation (BSX) raised its annual outlook after reporting strong sales in heart devices in Q1, beating revenue and earnings estimates.
• The company's cardiovascular sales saw significant growth, particularly in cardiology products, which contributed to the overall positive performance.
• The stock price surged as investors reacted positively to the company's robust Q1 earnings and revenue results, leading to an optimistic outlook for the future.
• Boston Scientific's solid product portfolio and financial performance in Q1 2025 have instilled confidence in investors, driving the stock price higher.

BSX Price Chart

BSX Technical Analysis

BSX News

Boston Scientific Raises Annual Outlook After Strong Heart Devices Sales In Q1, Announces CFO Transition - Boston Scientific ( NYSE:BSX )

Q1 revenue hit $4.66 billion vs. $4.57 billion est., with adjusted EPS at $0.75 beating $0.67 consensus. Cardiovascular sales grew 26.2% to $3.09 billion, led by a 29.8% jump in cardiology products. Feel unsure about the market's next move?

https://www.benzinga.com/general/health-care/25/04/44952308/boston-scientific-raises-annual-outlook-after-strong-heart-devices-sales-in-q1-announces-cfo-

BSX Q1 Earnings & Revenues Beat, Stock Up, 2025 View Raised

Boston Scientific's first-quarter 2025 performance benefits from the strength of its product portfolio.

https://www.zacks.com/stock/news/2453678/bsx-q1-earnings-revenues-beat-stock-up-2025-view-raised

Boston Scientific ( BSX ) Q1 Earnings and Revenues Top Estimates

Boston Scientific (BSX) delivered earnings and revenue surprises of 11.94% and 2.31%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2453360/boston-scientific-bsx-q1-earnings-and-revenues-top-estimates

Boston Scientific ( BSX ) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

Beyond analysts' top -and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.

https://www.zacks.com/stock/news/2450565/boston-scientific-bsx-q1-earnings-preview-what-you-should-know-beyond-the-headline-estimates

Trending Today

NEAR Protocol ($NEAR) Crypto Forecast: Down 5.7% Today

Movement ($MOVE) Crypto Forecast: Down 6.7% Today

Worldcoin ($WLD) Crypto Forecast: Down 5.2% Today

Sui ($SUI) Crypto Forecast: Down 5.1% Today

Memecoin ($MEME) Crypto Forecast: Down 5.5% Today

Bitcoin Cash ($BCH) Crypto Forecast: Up 5.0% Today

Immutable ($IMX) Crypto Forecast: Up 10.4% Today

Ethena ($ENA) Crypto Forecast: Down 5.2% Today

Natural Gas ($GAS) Commodity Forecast: Up 5.9% Today

Sirius XM Holdings Inc. ($SIRI) Stock Forecast: Up 5.1% Today

Boston Scientific Corporation Price History

04.03.2025 - BSX Stock was down 5.4%

• BSX stock saw a -1.55% decline, ending the day at $98.50.
• The stock has been consistently decreasing, with a 3.16% drop in the current session and a 1.95% decrease over the past month.
• Despite a 44.16% rise over the last year, investors are questioning whether BSX presents a better value proposition compared to other stocks in the Medical Products sector.
• The recent bearish movement seems to stem from profit-taking following significant prior gains, as investors reevaluate the company's value and growth potential vis-à-vis competitors like Phibro Animal Health (PAHC).

23.09.2024 - BSX Stock was down 5.0%

• Despite exceeding Q3 earnings and revenue estimates, BSX faced a significant bearish movement in the market today.
• Investor sentiment in the options market may have contributed to the downward pressure on BSX stock.
• A downgrade by a top Wall Street analyst could have influenced the bearish movement.
• The recent FDA approval for the FARAWAVE NAV Ablation Catheter and FARAVIEW Software, which was anticipated to drive up BSX shares, did not lead to a notable impact on the market today.

24.09.2024 - BSX Stock was up 2.3%

• Boston Scientific Corporation paused enrollment in the Farapulse study for drug-naive patients with irregular heart rhythm, a move that could enhance product safety and efficacy, potentially boosting investor confidence.
• Despite a slight premarket stock decline linked to a decrease in operating margin, BSX posted promising Q3 earnings surpassing revenue and EPS expectations, resulting in an improved annual forecast. This financial success likely contributed to the bullish market activity.
• Investors' optimistic outlook on Boston Scientific, demonstrated through options trading patterns, signifies a high level of confidence in the company's future growth prospects, further fueling the stock's uptrend.
• The strong performance in legacy businesses and robust demand for heart devices shown in the Q3 earnings report may have also been key factors in driving BSX towards a bullish market movement today.

08.00.2025 - BSX Stock was up 5.2%

• Boston Scientific's recent acquisition of Bolt Medical for over $440 million has expanded its cardiovascular treatment portfolio, showcasing growth and innovation in its offerings.
• Achieving a 52-week high reflects strong investor confidence and indicates potential for further gains going forward.
• Despite market fluctuations, Boston Scientific's resilience and positive performance highlight its strength and attractiveness to investors.
• The ongoing sales growth in endoscopy operations beyond the U.S. demonstrates Boston Scientific's adeptness in navigating competition and sustaining a competitive advantage in the market.

08.00.2025 - BSX Stock was up 6.2%

• BSX stock closed at $91.29 today, marking a +0.66% increase from the previous trading day.
• The positive movement in BSX stock is linked to the company's successful expansion internationally, especially in the field of endoscopy, which is anticipated to boost sales.
• Despite a downturn in the overall market, Boston Scientific showed strength, indicating resilience and potential growth in the near future.
• Market sentiment positions BSX as one of the standout performers in non-tech sectors for 2024, showing investor confidence in its future.

25.01.2025 - BSX Stock was down 3.2%

• Despite Boston Scientific's positive outlook for 2025 with expected strong revenue growth, the market might have reacted negatively due to concerns about potential challenges or uncertainties in achieving these ambitious targets.
• Investors may have been expecting even higher growth projections or may have been disappointed by other factors not mentioned, leading to the bearish movement in BSX stock.
• It's possible that profit-taking or a broader market correction influenced the stock's decline, overshadowing the positive expectations for the company's performance in the near future.

10.03.2025 - BSX Stock was up 7.5%

• BSX stock surged 6.8% in a bullish movement today.
• The positive price movement could be attributed to the market's optimism about the company's future growth prospects.
• Despite a recent drop in share price and earnings estimate revisions, investors seem to be confident in BSX's long-term potential, possibly driven by successful product developments or strategic partnerships.
• The overall bullish sentiment towards BSX today may indicate that investors believe in the company's ability to deliver strong financial performance in the coming periods.

09.11.2024 - BSX Stock was down 1.5%

• The bearish movement in BSX could be attributed to insider selling activity by Emily Woodworth, a senior executive at the company, potentially raising concerns among investors about the company's future prospects.
• The overall market sentiment might have also played a role in the stock's decline, as investors may have been cautious due to uncertainties in the broader market.
• Despite the dip, BSX's long-term growth prospects and innovative product pipeline could still make it an attractive investment opportunity for those looking to capitalize on the healthcare sector's potential.

23.03.2025 - BSX Stock was up 5.5%

• BSX stock demonstrated significant bullish momentum recently.
• The company disclosed Q1 earnings and revenues that exceeded expectations, signaling robust financial results.
• Market participants seem to be responding favorably to the strong performance, displaying trust in Boston Scientific's potential for growth.
• The impressive earnings and revenue figures are likely fueling heightened investor confidence and enthusiasm for the stock, contributing to its current upward trajectory.

23.03.2025 - BSX Stock was up 5.5%

• Boston Scientific Corporation (BSX) raised its annual outlook after reporting strong sales in heart devices in Q1, beating revenue and earnings estimates.
• The company's cardiovascular sales saw significant growth, particularly in cardiology products, which contributed to the overall positive performance.
• The stock price surged as investors reacted positively to the company's robust Q1 earnings and revenue results, leading to an optimistic outlook for the future.
• Boston Scientific's solid product portfolio and financial performance in Q1 2025 have instilled confidence in investors, driving the stock price higher.

07.02.2025 - BSX Stock was down 5.1%

• The decline in BSX stock was influenced by doubts surrounding the excessively positive views from Wall Street, causing investors to question the stock's true value and associated risks.
• Despite acquiring SoniVie for $400 million to enhance its hypertension treatment portfolio, there are concerns about the impact on BSX's 2025 EPS, possibly affecting its short-term financial performance and outlook.
• Market uncertainties about integrating SoniVie into Boston Scientific's operations and realizing the expected benefits might be driving a cautious investor sentiment.

10.03.2025 - BSX Stock was down 5.3%

• Analysts view BSX as a promising investment, yet the stock saw a decline, possibly linked to investors capitalizing on profits.
• Following a notable increase in BSX's share price in the previous session, today's drop suggests a shift in market sentiment.
• The stock price of BSX declined by 1.55%, potentially due to investors seizing the opportunity to secure profits following the recent upsurge.